Mazza, Gina L. http://orcid.org/0000-0002-5305-6193
Petersen, Molly M.
Ginos, Brenda
Langlais, Blake T.
Heon, Narre
Gounder, Mrinal M.
Mahoney, Michelle R.
Zoroufy, Alexander J.
Schwartz, Gary K.
Rogak, Lauren J.
Thanarajasingam, Gita
Basch, Ethan
Dueck, Amylou C.
Clinical trials referenced in this document:
Documents that mention this clinical trial
Missing data strategies for the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in Alliance A091105 and COMET-2
https://doi.org/10.1007/s11136-021-02968-1
Documents that mention this clinical trial
Molecular alterations and emerging targets in castration resistant prostate cancer
https://doi.org/10.1016/j.ejca.2013.12.004
Missing data strategies for the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in Alliance A091105 and COMET-2
https://doi.org/10.1007/s11136-021-02968-1
Funding for this research was provided by:
Daniel J. Sargent, Ph.D., Career Development Award in Cancer Research
National Cancer Institute (UG1CA189823, UG1CA233373, UG1CA232760, UG1CA233290, U01CA233046)
Bayer
exelixis
Article History
Accepted: 5 August 2021
First Online: 21 August 2021
Change Date: 11 October 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s11136-021-03000-2
Declarations
:
: The authors declare that they have no competing interests pertaining to this analysis. Competing interests pertaining to Alliance A091105 were reported in Gounder et al. Competing interests pertaining to COMET-2 were reported in Basch et al.
: Alliance A091105 and COMET-2 were conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. The Alliance A091105 and COMET-2 protocols were approved by the institutional review board or ethics committee at each participating site.
: All Alliance A091105 and COMET-2 patients provided written informed consent for participation.
: Alliance A091105 and COMET-2 patients provided written informed consent for publication.